US FDA accepts sBLA for GSK’s Jemperli for broader endometrial cancer use

The latest acceptance will allow GSK to potentially expand use of Jemperli for treatment of primary advanced or recurrent endometrial cancer in adult patients. Credit: Elen Sher/Unsplash.